继发性脂肪性肝炎的诊断与管理
本文综述了可导致、模拟或加重非酒精性脂肪性肝病(NAFLD)的继发性病因,包括罕见遗传性肝病、代谢病、肠道疾病、内分泌疾病及药物。与原发性NAFLD不同,许多继发性病因有特异性治疗手段,因此诊断时应筛查继发性病因并治疗原发病。常见遗传变异可能调节肝病进展风险,基因分型或有助于评估继发性脂肪肝患者进展风险。
要点
- 诊断脂肪肝时应筛查继发性病因,因许多病因有特异性治疗。
- 继发性病因包括遗传代谢病、肠道疾病、内分泌病及药物。
- 常见遗传变异可能预测脂肪肝进展为纤维化、肝硬化或肝癌的风险。
核心结论
- 继发性脂肪肝病应被识别并治疗原发病以阻止进展。
- 常见遗传变异可能有助于评估继发性脂肪肝病的进展风险。
研究设计与样本
- 本文为综述,检索范围未明确报告。
主要发现
- 多种罕见遗传性肝病、代谢病、肠道病、内分泌病及药物可导致、模拟或加重NAFLD。
- 许多继发性NAFLD病因有特异性治疗干预手段。
- 涉及脂质处理与代谢的多个基因的常见变异调节NAFLD、酒精性肝病和病毒性肝炎从脂肪变进展为纤维化、肝硬化及肝细胞癌的风险。
临床怎么用
- 在脂肪肝患者的诊断检查中应考虑继发性病因。
- 应治疗 underlying 疾病以阻止疾病进展。
- 可考虑对常见肝病进展风险变异进行基因分型以评估晚期肝病风险。
局限性
- 本文为综述,未报告系统检索策略与纳入标准。
- 基因分型用于继发性脂肪肝病风险分层的效用为推测性,未提供实证数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The term non-alcoholic fatty liver disease (NAFLD) was originally coined to describe hepatic fat deposition as part of the metabolic syndrome. However, a variety of rare hereditary liver and metabolic diseases, intestinal diseases, endocrine disorders and drugs may underlie, mimic, or aggravate NAFLD. In contrast to primary NAFLD, therapeutic interventions are available for many secondary causes of NAFLD. Accordingly, secondary causes of fatty liver disease should be considered during the diagnostic workup of patients with fatty liver disease, and treatment of the underlying disease should be started to halt disease progression. Common genetic variants in several genes involved in lipid handling and metabolism modulate the risk of progression from steatosis to fibrosis, cirrhosis and hepatocellular carcinoma development in NAFLD, alcohol-related liver disease and viral hepatitis. Hence, we speculate that genotyping of common risk variants for liver disease progression may be equally useful to gauge the likelihood of developing advanced liver disease in patients with secondary fatty liver disease.
引用
- Liebe R, Esposito I, Bock HH, et al. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol. 2021. PMID: 33577920. doi:10.1016/j.jhep.2021.01.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。